ACCP HO PRN Journal Club_Epcoritamab
<p>Article: Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous cd3xcd20 bispecific t-cell-engaging antibody, in relapsed or refractory large b-cell lymphoma: dose expansion in a phase i/ii trial. <i>J Clin Oncol</i>. 2023;41(12):2238-2247.</p><p><br></p><p>Presenter: Edith Ford, PharmD</p><p>Position: PGY1 Oncology Pharmacy Resident at Mayo Clinic in Phoenix, AZ</p><p><br></p><p>Mentor: David Quach, PharmD, BCPS, BCOP</p><p>Position: Oncology Clinical Pharmacist Specialist at Nebraska Medicine in Omaha, NE</p>